Treatment of Adenocarcinoma of the Appendix in Goblet Cell Adenocarcinoma
Goblet cell adenocarcinoma (GCA) of the appendix is a rare histologic subtype that presents distinct management considerations. This page outlines the clinical scenario and provides access to the complete structured protocol.
Clinical scenario
Goblet cell adenocarcinoma — also commonly referred to as "goblet cell carcinoid" — accounts for approximately 14–19% of primary appendix cancers. Recent evidence indicates that GCA behaves more like adenocarcinoma than neuroendocrine carcinoma, both in immunohistochemical profile and in biologic behavior. This distinction informs the treatment approach.
Treatment approach (partial overview)
When lymph node involvement is present, adjuvant systemic therapy may be indicated. The complete protocol — including specific regimen selection, sequencing, and duration — is available in the full reference below.
Full protocol details are behind the link below.
References
- Goblet cell adenocarcinoma (GCA), also commonly referred to as "goblet cell carcinoid," is a rare tumor type accounting for approximately 14 to 19% of primary appendix cancers.
- Recent studies have shown that GCAs are actually closer to adenocarcinoma than neuroendocrine carcinoma in terms of both immunohistochemical profile and biologic behavior.
- If lymph node involvement is present, adjuvant systemic therapy with a 5-fluorouracil–based regimen is recommended for 6 months.
DOI: 10.1055/s-0035-1564433
View source ↗